Surgery Partners Analyst Price Targets

Wall Street analyst price targets and consensus rating for Surgery Partners (SGRY).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$24Upside to Avg. PT+71.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	RBC Capital	Ben Hendrix	Maintained	Outperform	$19
Sep 18, 2026	TD Cowen	Ryan Langston	Maintained	Buy	$19
Sep 14, 2026	JP Morgan	Benjamin Rossi	PT Raise	Neutral	$14→$15
Aug 11, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$17→$19
Aug 11, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$20→$19
Aug 11, 2026	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$18
Mar 5, 2026	TD Cowen	Ryan Langston	PT Cut	Buy	$28→$20
Mar 5, 2026	UBS	A.J. Rice	PT Cut	Buy	$29→$21
Mar 5, 2026	Mizuho	Ann Hynes	PT Cut	Outperform	$19→$17
Mar 4, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$31→$20
Mar 3, 2026	Barclays	Andrew Mok	PT Cut	Equal-Weight	$18→$14
Dec 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$22→$19
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$27→$20
Nov 21, 2025	Barclays	Andrew Mok	PT Cut	Equal-Weight	$24→$18
Nov 17, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$28→$22
Nov 13, 2025	UBS	A.J. Rice	PT Cut	Buy	$34→$29
Nov 11, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$35→$31
Nov 11, 2025	Benchmark	Bill Sutherland	PT Cut	Buy	$35→$30
Oct 7, 2025	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$36
Sep 18, 2025	JP Morgan	Benjamin Rossi	Assumes	Neutral	$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

JP Morgan analyst Benjamin Rossi maintains Surgery Partners (NASDAQ:SGRY) with a Neutral and raises the price target from $14 to $15.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $20 to $19.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $18 price target.

Benzinga Newsdesk

Surgery Partners Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Surgery Partners Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

People Also Watch

People Also Watch

Surgery Partners Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Surgery Partners Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PROTD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PROJP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PROTD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRORBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PROCantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

People Also Watch

People Also Watch

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target